The PSK and docetaxel treatments alone resulted in higher numbers of TILs than in control mice, and the addition of PSK to docetaxel increased both tumor infiltrating CD4+ T cells compared to PSK or docetaxel alone (p<0.05) and CD8+ T cell numbers compared to docetaxel alone (p<0.05) (Fig. 5), suggesting an enhancing effect of the combined treatment on tumor infiltrating T cells. This evidence concerns the gene CD4 and neoplasm.